The settlement terminates a licensing agreement signed between Rockefeller and Ligand in 1992 related to patents and know-how surrounding peptidyl hormone-mediated gene expression technology discovered primarily by a Rockefeller scientist.
Top executives last week from Alexandria Real Estate Equities, BioMed Realty Trust, and HCP said life-sci shops are increasingly skittish about leasing new space for the long term, leading the REITs to reduce spending on construction and renovation projects this year.
Both companies separately last week announced plans to expand the scope of their respective businesses in response to what they said is increased desire from customers to outsource their array production and array-based research projects.
Ocarina Networks said this week that Cornell University's Center for Advanced Computing is testing its system for compressing large amounts of life-science data, including data from second-generation sequencers.
Affy aims to target downstream genomic-analysis markets with the products gained through its acquisitions of Panomics and True Materials last year, roll out new genotyping assays on its GeneTitan array platform, and consolidate its manufacturing facilities.
Gentel believes its APiX assays and platform will be attractive to both its core pharma customers, who are interested in adding new assays to compound screening programs, and to new academic customers, who might be attracted to the system's lower cost.